LipoMedix Announces Manufacturing Agreement with ForDoz for Promitil® JERUSALEM, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- LipoMedix, a clinical-stage, oncology-focused pharmaceutical company involved in the development of innovative, safe and effective cancer therapy...

LipoMedix Announces Publication of Positive Phase 1 Data for Promitil® (PL-MLP) in Research Journal Investigational New Drugs JERUSALEM, Jan. 23, 2020 (GLOBE NEWSWIRE) -- LipoMedix, a clinical-stage, oncology-focused pharmaceutical company, involved in the development of innovative, safe and effective cancer therapy based...

LipoMedix Appoints New Members to Board of Directors and Creates New Executive Committee Jerusalem, Aug. 05, 2019 (GLOBE NEWSWIRE) --  LipoMedix Pharmaceuticals Ltd., a clinical and development-stage company focused on the development of an innovative, safe and effective cancer therapy...

LipoMedix to Present New Clinical Data on Promitil® at American Association for Cancer Research (AACR) Annual Meeting 2019 Givat Ram High-Tech Village, Jerusalem, March 29, 2019 (GLOBE NEWSWIRE) -- Lipomedix, a clinical-stage, oncology-focused pharmaceutical company, involved in the development of innovative, safe and...

Lipomedix Announces Initiation of Phase 1b Trial (LIPORAD-2018) of Promitil® in Combination with Radiotherapy in Patients with Advanced Cancer. Givat Ram High-Tech Village, Jerusalem, March 04, 2019 (GLOBE NEWSWIRE) -- Lipomedix, a clinical-stage, oncology-focused pharmaceutical company, involved in the development of innovative, safe and...